Abstract: A method of stabilizing pharmaceutical compositions containing cefovecin sodium salt which is in an amorphous or other disordered state is disclosed.

Abstract: A composition for nasal administration comprising varenicline or its pharmaceutically acceptable salt and at least one excipient. The invention also provides a composition for buccal administration comprising varenicline or its pharmaceutically acceptable salt and at least one excipient to form a solid dosage form, wherein the solid dosage form disintegrates in an oral cavity at body temperature and may adhere to body tissue of the oral cavity; a composition for pulmonary administration comprising varenicline or its pharmaceutically acceptable salt and at least one excipient; and, a method for reducing nicotine addiction, aiding in the cessation of, or lessening of tobacco use in a subject.

Abstract: A fast disintegrating dosage form of varenicline comprising an effective amount of varenicline or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the dosage form disintegrates in a patient's oral cavity in less than three minutes. Also provided are a method for reducing nicotine addiction, aiding in the cessation of, or lessening of tobacco use in a subject by administering to the subject an effective amount of the fast disintegrating dosage form of varenicline or pharmaceutically acceptable salts thereof; a method of treating a disorder or condition by administering an effective amount of the fast disintegrating dosage form of varenicline; and, various methods of manufacturing or forming an immediate dosage form of varenicline.

Abstract: The invention provides a novel class of 6-(isoxazolinyl)methyl penicillanic acid 1,1-dioxide compounds having the formula: ##STR1## wherein M, X, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are described in the specification;which exhibit activity as a .beta.-lactamase inhibitor.